Sopharma AD (BUL:SFA)

Market Cap	1.77B +84.5%
Revenue (ttm)	2.51B +22.1%
Net Income	124.18M +50.2%
EPS	0.44 +183.9%
Shares Out	519.26M
PE Ratio	7.82
Forward PE	n/a
Dividend	0.06 (1.64%)
Ex-Dividend Date	Dec 18, 2025

Volume	107,394
Average Volume	44,332
Open	1.785
Previous Close	1.790
Day's Range	1.715 - 1.785
52-Week Range	1.410 - 2.900
Beta	0.04
RSI	31.07
Earnings Date	Mar 2, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices...

• Industry: Pharmaceutical Preparations
• Founded: 1933
• Employees: 5,905
• Stock Exchange: Bulgarian Stock Exchange
• Ticker Symbol: SFA

Financial Performance

In 2024, Sopharma AD's revenue was 2.14 billion, an increase of 13.27% compared to the previous year's 1.89 billion. Earnings were 77.85 million, a decrease of -18.89%.